NCT03054298 · ADVERSE EVENTS

Adverse events

CAR T Cells in Mesothelin Expressing Cancers · Source last updated 2025-04-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 7 years
Other-event reporting threshold: 0%

Cohort 4 was closed without any subjects being enrolled. Subjects were transitioned to a separate long-term follow-up (LTFU) protocol for a variety of reasons (e.g. disease progression, receipt of alternative therapy, PI discretion, etc). Only protocol-defined adverse events (PDAEs) were collected/reported on the separate LTFU protocol, and death due to disease progression was not considered a PDAE. PDAEs are defined in the protocol section 8.1.1.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Cohort 1 Single dose of 1-3x10\^7 huCARTmeso cells/m\^2 huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..	1 / 3	3 / 3	3 / 3
Cohort 2 Cyclophosphamide 1 gram/m\^2 administered 2-4 days prior to a single dose of 1-3x10\^7 huCARTmeso cells/m\^2 huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..	1 / 3	3 / 3	3 / 3
Cohort 3 PERMANENTLY CLOSED huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..	2 / 2	2 / 2	2 / 2
Cohort 4 PERMANENTLY CLOSED huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..	0 / 0	0 / 0	0 / 0
Cohort 5 Single dose of 1-3x10\^7 huCART-meso cells/m\^2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen. huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..	1 / 2	2 / 2	2 / 2
Cohort 6 Cyclophosphamide 1 gram/m\^2 administered 2-4 days prior to dose of 1-3x10\^7 huCART-meso cells/m\^2 via IV infusion on Day 0. This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells. huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..	4 / 6	6 / 6	4 / 6
Cohort 7 Cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day given over 3 days by IV infusion followed by a single dose of 1-3x10\^7 huCART-meso cells/m\^2 via intraperitoneal (i.p.) administration. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells. huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..	6 / 6	6 / 6	6 / 6

Group identifiers: EG000: Cohort 1 · EG001: Cohort 2 · EG002: Cohort 3 · EG003: Cohort 4 · EG004: Cohort 5 · EG005: Cohort 6 · EG006: Cohort 7

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
1
num At Risk
3
group Id
EG002
num Affected
1
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Febrile neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Cardiac arrest
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
1
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
2
num At Risk
6
term
Abdominal pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Colitis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Diarrhea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Other (Viral gastroenteritis)
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Gastroparesis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
1
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Nausea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Vomiting
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Edema limbs
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Fatigue

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
stats
group Id
EG000
num Affected
2
num At Risk
3
group Id
EG001
num Affected
2
num At Risk
3
group Id
EG002
num Affected
1
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
1
num At Risk
2
group Id
EG005
num Affected
3
num At Risk
6
group Id
EG006
num Affected
6
num At Risk
6
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Atrial fibrillation
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Chest pain - cardiac
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Palpitations
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
1
num At Risk
3
group Id
EG002
num Affected
1
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
1
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
3
num At Risk
6
term
Sinus tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Supraventricular tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Ear and labyrinth disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Ear pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Ear and labyrinth disorders
stats
group Id
EG000
num Affected
1
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Tinnitus
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Eye disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Other (anisocoria)
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Eye disorders
stats
group Id
EG000
num Affected
1
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Other (burning sensation)
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Eye disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Eye pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Abdominal distension

Complete source fields

description

event Groups

deaths Num Affected
3
deaths Num At Risk
3
description
Single dose of 1-3x10\^7 huCARTmeso cells/m\^2 huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
id
EG000
other Num Affected
3
other Num At Risk
3
serious Num Affected
1
serious Num At Risk
3
title
Cohort 1
deaths Num Affected
3
deaths Num At Risk
3
description
Cyclophosphamide 1 gram/m\^2 administered 2-4 days prior to a single dose of 1-3x10\^7 huCARTmeso cells/m\^2 huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
id
EG001
other Num Affected
3
other Num At Risk
3
serious Num Affected
1
serious Num At Risk
3
title
Cohort 2
deaths Num Affected
2
deaths Num At Risk
2
description
PERMANENTLY CLOSED huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
id
EG002
other Num Affected
2
other Num At Risk
2
serious Num Affected
2
serious Num At Risk
2
title
Cohort 3
deaths Num Affected
0
deaths Num At Risk
0
description
PERMANENTLY CLOSED huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
id
EG003
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Cohort 4
deaths Num Affected
2
deaths Num At Risk
2
description
Single dose of 1-3x10\^7 huCART-meso cells/m\^2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen. huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
id
EG004
other Num Affected
2
other Num At Risk
2
serious Num Affected
1
serious Num At Risk
2
title
Cohort 5
deaths Num Affected
4
deaths Num At Risk
6
description
Cyclophosphamide 1 gram/m\^2 administered 2-4 days prior to dose of 1-3x10\^7 huCART-meso cells/m\^2 via IV infusion on Day 0. This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells. huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
id
EG005
other Num Affected
6
other Num At Risk
6
serious Num Affected
4
serious Num At Risk
6
title
Cohort 6
deaths Num Affected
6
deaths Num At Risk
6
description
Cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day given over 3 days by IV infusion followed by a single dose of 1-3x10\^7 huCART-meso cells/m\^2 via intraperitoneal (i.p.) administration. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells. huCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..
id
EG006
other Num Affected
6
other Num At Risk
6
serious Num Affected
6
serious Num At Risk
6
title
Cohort 7

frequency Threshold

other Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
stats
group Id
EG000
num Affected
2
num At Risk
3
group Id
EG001
num Affected
2
num At Risk
3
group Id
EG002
num Affected
1
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
1
num At Risk
2
group Id
EG005
num Affected
3
num At Risk
6
group Id
EG006
num Affected
6
num At Risk
6
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Atrial fibrillation
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Chest pain - cardiac
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Palpitations
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
1
num At Risk
3
group Id
EG002
num Affected
1
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
1
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
3
num At Risk
6
term
Sinus tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Supraventricular tachycardia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Ear and labyrinth disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Ear pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Ear and labyrinth disorders
stats
group Id
EG000
num Affected
1
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Tinnitus
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Eye disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Other (anisocoria)
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Eye disorders
stats
group Id
EG000
num Affected
1
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Other (burning sensation)
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Eye disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Eye pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Abdominal distension

serious Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Anemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
1
num At Risk
3
group Id
EG002
num Affected
1
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Febrile neutropenia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Cardiac disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Cardiac arrest
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
1
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
2
num At Risk
6
term
Abdominal pain
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Colitis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Diarrhea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
1
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Other (Viral gastroenteritis)
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Gastroparesis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
1
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Nausea
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Gastrointestinal disorders
stats
group Id
EG000
num Affected
0
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
1
num At Risk
6
term
Vomiting
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Edema limbs
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
3
group Id
EG001
num Affected
0
num At Risk
3
group Id
EG002
num Affected
0
num At Risk
2
group Id
EG003
num At Risk
0
group Id
EG004
num Affected
0
num At Risk
2
group Id
EG005
num Affected
0
num At Risk
6
group Id
EG006
num Affected
0
num At Risk
6
term
Fatigue

time Frame

7 years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice